Literature DB >> 19767151

High-grade glioma mouse models and their applicability for preclinical testing.

Nienke A de Vries1, Jos H Beijnen, Olaf van Tellingen.   

Abstract

High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults. Unfortunately, despite great efforts in finding better therapies, high-grade glioma remains among the most devastating and deadliest of all human cancers. During recent years, genetic and molecular alterations that underlie this disease have been identified and advanced our basic knowledge about gliomagenesis. Moreover, understanding the molecular biology has also led to the development of genetically engineered mouse models that resemble many of the features of human gliomas. Ideally, such "patient-like" models should be instrumental for preclinical testing of novel therapeutics, but thus far they have not yet been widely implemented for this purpose. This review will discuss the advantages and shortcomings of the established high-grade glioma mouse models with emphasis on their potential applicability for preclinical testing of novel drugs and treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767151     DOI: 10.1016/j.ctrv.2009.08.011

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  33 in total

Review 1.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model.

Authors:  Mohamed A Elmeliegy; Angel M Carcaboso; Lionel M L Chow; Ziwei M Zhang; Christopher Calabrese; Stacy L Throm; Fan Wang; Suzanne J Baker; Clinton F Stewart
Journal:  J Pharm Sci       Date:  2011-08-11       Impact factor: 3.534

3.  CEREBRAL ORGANOIDS AS A MODEL FOR GLIOBLASTOMA MULTIFORME.

Authors:  Nathaniel Silvia; Guohao Dai
Journal:  Curr Opin Biomed Eng       Date:  2020-03-25

4.  Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.

Authors:  Adarsh Shankar; Meenu Jain; Mei Jing Lim; Kartik Angara; Peng Zeng; Syed A Arbab; Asm Iskander; Roxan Ara; Ali S Arbab; Bhagelu R Achyut
Journal:  J Cancer Sci Ther       Date:  2016-07-15

5.  Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.

Authors:  Margaret Folaron; Mukund Seshadri
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

6.  Evolutionary etiology of high-grade astrocytomas.

Authors:  Yurong Song; Qian Zhang; Burak Kutlu; Simone Difilippantonio; Ryan Bash; Debra Gilbert; Chaoying Yin; T Norene O'Sullivan; Chunyu Yang; Serguei Kozlov; Elizabeth Bullitt; Ken D McCarthy; Tal Kafri; David N Louis; C Ryan Miller; Leroy Hood; Terry Van Dyke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-10       Impact factor: 11.205

7.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.

Authors:  Robert S McNeill; Ralf S Schmid; Ryan E Bash; Mark Vitucci; Kristen K White; Andrea M Werneke; Brian H Constance; Byron Huff; C Ryan Miller
Journal:  J Vis Exp       Date:  2014-08-12       Impact factor: 1.355

Review 8.  Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells.

Authors:  Shreyas S Rao; John J Lannutti; Mariano S Viapiano; Atom Sarkar; Jessica O Winter
Journal:  Tissue Eng Part B Rev       Date:  2013-10-30       Impact factor: 6.389

9.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

Review 10.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.